Filter Results:
(338)
Show Results For
- All HBS Web (338)
- Faculty Publications (228)
Show Results For
- All HBS Web (338)
- Faculty Publications (228)
- 01 Sep 2006
- News
Gift of Gab
then delivered a prepared talk on a topic of their choice. Subjects ranged from the pharmaceutical industry to the relative merits of cats vs. dogs, while Kim’s presentation took a humorous yet thoughtful approach to lessons learned in... View Details
- 01 Jun 2012
- News
The Power of Philanthropy
When their son Joey died of cystic fibrosis in 1986 at age 12, Kathy and Joe O’Donnell (MBA 1971) vowed to fight the disease. O’Donnell, at the time the president of the Boston Concessions Group, joined with Vertex Pharmaceuticals and the... View Details
- 01 Feb 2002
- News
Health Industry Alumni Convene for Conference
and CEO of Mediconsulting, Inc., spoke about creating a better model for business collaborations between biotech and pharmaceutical firms. Said Klietmann, the conference's biotechnology chair and a lecturer in pathology at Harvard Medical... View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs what kinds of services. These things are all connected, and changing one piece, or plugging an... View Details
- 01 Mar 2006
- News
Using IT to Heal U.S. Health Care
Association’s conference held on campus in early November. The three-day conference included presentations by industry executives, government officials, and HBS faculty on topics ranging from trends in the biotech and pharmaceutical... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
"Bank of America is interested in accessing innovative digital technologies that will help it redefine how banking is done," Sato says. "The bank sees this as an opportunity to fuel its continued competitive presence in a... View Details
- 24 Apr 2014
- News
Giving hope and inspiration to cancer patients around the globe
Every new day is a good day for Kathryn E. Giusti (MBA 1985) since that morning in 1996 when her oncologist told her to get her affairs in order because she had a rare blood cancer, with three years to live. Leveraging her past experience as a View Details
- 24 Apr 2014
- News
A passion for the sea doubles the percent of ocean set aside for conservation
Ernesto Bertarelli (MBA 1993), an America’s Cup–winning sailor and avid scuba diver, understands the importance of protecting marine ecosystems. The former owner and CEO of the pharmaceutical and biotechnology company Serono has provided... View Details
- 02 Oct 2000
- Research & Ideas
The Dubious Logic of Global Megamergers
with their mega-deals, you can exploit that fact to improve your own competitive position. For instance, while pharmaceutical players such as Glaxo Wellcome and SmithKline Beecham have made headlines with their merger news, one large... View Details
Keywords: by Pankaj Ghemawat & Fariborz Ghadar
- February 2006 (Revised February 2009)
- Case
AIDS in Brazil
By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details
Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- 24 Jul 2014
- Op-Ed
Reform Tax Law to Keep US Firms at Home
Editor's Note. Given a veritable flood over the last year of corporate "inversions"—US companies that reincoporate in other countries to take advantage of favorable tax rates and business regulations—lawmakers in Washington D.C. are debating how to respond.... View Details
- October 1987 (Revised November 1994)
- Case
Boston Fights Drugs (A): Designing Communications Research
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their... View Details
Keywords: Budgets and Budgeting; Misleading and Fraudulent Advertising; Communication Intention and Meaning; Brands and Branding; Performance Evaluation; Research and Development; Segmentation; Pharmaceutical Industry; Boston
Rangan, V. Kasturi. "Boston Fights Drugs (A): Designing Communications Research." Harvard Business School Case 588-031, October 1987. (Revised November 1994.)
- 2023
- Working Paper
Market Exclusivity and Innovation: Evidence From Antibiotics
By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)